LifeSci Capital analyst Sam Slutsky maintained a Hold rating on Third Harmonic Bio, Inc. (THRD – Research Report) today. The company’s shares closed today at $4.94.
Slutsky covers the Healthcare sector, focusing on stocks such as Celldex, BELLUS Health, and Aeglea Biotherapeutics. According to TipRanks, Slutsky has an average return of 7.1% and a 43.84% success rate on recommended stocks.
Currently, the analyst consensus on Third Harmonic Bio, Inc. is a Hold with an average price target of $5.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $24.60 and a one-year low of $3.75. Currently, Third Harmonic Bio, Inc. has an average volume of 92.75K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. The company’s lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
Read More on THRD:
